Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Electric Vehicles and Future Mobility vs Vertex Pharmaceuticals Incorporated — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $30.53, while Vertex Pharmaceuticals Incorporated trades at $528 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals.
| KARS | VRTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $529.65 |
52-Week Low | $25.59 | $376.62 |
Market Cap | — | $134.25B |
Enterprise Value | — | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KARS trades at $30.86, up 2.51% today, with a bullish technical signal but bearish moving averages. Recent news highlights global EV sales growth, particularly in Europe and China, though U.S. adoption lags. The stock shows strong momentum with RSI_6 at 80.23 indicating overbought conditions, while support and resistance cluster around $30-$31.
The outlook for KARS is mixed; positive EV industry trends support growth, but high RSI suggests near-term pullback risk. Investment opportunity lies in global EV expansion, while risks include U.S. market hesitation and competitive pressures from Chinese automakers.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
